Edwards Lifesciences heads into its May 7 Q1 2026 results with analysts tilting bullish after a flurry of target increases — but the debate is sharpening around whether the company can defend its operating margins while sustaining double-digit TMTT growth.
The post-earnings analyst response to Q4 has been notably constructive. Barclays raised its target to $110, maintaining Overweight. BTIG moved to $100 from $98 with a Buy. Evercore ISI and Truist both nudged targets higher, while Baird lifted to $87. Only Canaccord cut — trimming modestly to $85, still a Hold. The consensus mean price target of $97.15 implies roughly 16% upside from the current $83.98, and the Street's direction of travel is clearly positive heading into the print. Goldman Sachs cut its target to $95 from $108 in February, a significant trim that tempers the bull case slightly, though the firm held its Buy rating.
The bull case rests on product momentum: TAVR revenues growing at roughly 10% year-over-year, TMTT surging 48% on Pascal and Evoque adoption, and management guiding the full year toward $6.4–$6.8 billion in total revenue. EPS momentum ranks in the 77th percentile on a 30-day basis, and 67th percentile over 90 days — a sign that forward estimates have been steadily improving. The bear case is more surgical. Adjusted operating margin came in at 23.7% against a 25.9% consensus expectation, with elevated SG&A as the culprit. TAVR market growth is maturing, and competition is building. Bears argue that the revenue mix shifting toward higher-cost TMTT rollout could keep margins under pressure even as the top line grows.
Short interest is not a meaningful part of this story. At 1.7% of the free float — down roughly 10% over the past month — there is no material short conviction at work. Borrowing costs are low at 0.43% and borrow availability is ample, so there is no squeeze dynamic in play. The put/call ratio has edged above its 20-day average at 1.57, though the z-score of 0.82 is modest — more a mild skew toward hedging than a strong directional bet. The ORTEX short score of 30.3 reinforces the picture: short sellers are not a primary force here.
The May 7 print is therefore a clean test of whether Edwards can close the gap between its top-line growth story and the margin profile the Street is demanding to justify a forward PE above 26.
See the live data behind this article on ORTEX.
Open EW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
